Acumen Hypotension Prediction Index – EV1000 Clinical Platform vs HeartFlow Analysis

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
Acumen Hypotension Prediction Index – EV1000 Clinical Platform
by Edwards Lifesciences
VS
HeartFlow Analysis
by HeartFlow

AI Verdict

These tools are adjacent in the broader field of Cardiology AI but serve distinct clinical purposes. Acumen HPI focuses on real-time prediction and management of hypotensive events in acute care settings, leveraging continuous hemodynamic monitoring data. HeartFlow Analysis, conversely, provides non-invasive diagnostic insights for coronary artery disease by creating 3D models from CT scans to aid in treatment planning.

Choose Acumen Hypotension Prediction Index – EV1000 Clinical Platform if…

Choose Acumen Hypotension Prediction Index if you need real-time, predictive insights to proactively manage hemodynamic instability in critically ill or surgical patients. This tool is ideal for anesthesiologists and critical care teams aiming to reduce intraoperative or ICU hypotension by anticipating events up to 15 minutes in advance and understanding underlying causes.

View Acumen Hypotension Prediction Index – EV1000 Clinical Platform →

Choose HeartFlow Analysis if…

Choose HeartFlow Analysis if you require a non-invasive, AI-powered diagnostic solution for assessing coronary artery disease. This platform is best suited for cardiologists and radiologists seeking to evaluate the functional significance of coronary stenoses and characterize plaque using 3D models derived from standard CT scans, aiding in treatment planning and risk stratification.

View HeartFlow Analysis →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Acumen Hypotension Prediction Index – EV1000 Clinical Platform HeartFlow Analysis
Pricing Unknown Contact vendor for pricing
Deployment On-premise (integrated with EV1000 clinical platform and HemoSphere advanced monitoring platform) Cloud-based (AWS)
BAA Available Unknown Yes AI-estimated
FDA Status Cleared AI-estimated Yes AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Acumen HPI is integrated directly into the Edwards Lifesciences HemoSphere Advanced Monitoring Platform, providing continuous, real-time insights and smart alerts at the point of care for immediate clinical action. This direct integration into a familiar monitoring environment makes it highly usable for clinicians in critical care settings. HeartFlow Analysis, while user-friendly for its purpose, involves uploading CT scans and reviewing results, which is a different workflow.

Clinical Value

HeartFlow Analysis

HeartFlow Analysis offers significant clinical value by providing a non-invasive diagnostic solution for coronary artery disease, potentially reducing the need for invasive procedures. Its widespread coverage by Medicare and most U.S. commercial payers, along with established Category I CPT codes and CMS payment rates, strongly indicates recognized clinical utility and tangible economic value within the healthcare system. While Acumen HPI also addresses a critical clinical need, HeartFlow's established reimbursement pathways highlight a broader acceptance and integration into standard clinical practice.

Pricing & Value

HeartFlow Analysis

While both tools require contacting the vendor for specific pricing, HeartFlow Analysis explicitly details a fee-for-service model with established Category I CPT codes and CMS payment rates. This transparency regarding reimbursement mechanisms provides a clear pathway for healthcare providers to understand the economic value and financial viability of adopting the technology. Acumen HPI lacks this level of detail regarding its pricing structure and reimbursement.

Enterprise Readiness

HeartFlow Analysis

Both tools are HIPAA compliant and FDA cleared, demonstrating foundational readiness. However, HeartFlow Analysis, with its cloud-based (AWS) deployment, offers greater flexibility and scalability for enterprise-wide adoption without requiring specific hardware integration beyond standard CT scanners. Its established reimbursement pathways also simplify financial integration for healthcare systems.

Innovation

HeartFlow Analysis

HeartFlow Analysis demonstrates superior innovation by leveraging AI and Computational Fluid Dynamics (CFD) to create personalized 3D models and non-invasively derive Fractional Flow Reserve from CT (FFRct) analysis. This approach provides functional insights from standard imaging, offering a groundbreaking alternative to traditional invasive diagnostic methods. Acumen HPI's predictive analytics for hypotension is also innovative, but HeartFlow's combination of AI, 3D modeling, and CFD for functional assessment from non-invasive imaging represents a more significant leap in diagnostic technology.

Support & Docs

Tie

Neither the provided structured facts nor readily available public information offer specific comparative details regarding the depth, accessibility, or quality of support and documentation for either product. Both are offered by established medical technology companies, implying a professional standard of support and resources for their users.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Acumen Hypotension Prediction Index – EV1000 Clinical Platform HeartFlow Analysis
Tool Name Acumen Hypotension Prediction Index u2013 EV1000 Clinical Platform HeartFlow Analysis
Company Edwards Lifesciences HeartFlow
Primary Clinical Focus Predicting and managing hypotension before it occurs; insights into hemodynamic instability and potential causes to help reduce intraoperative hypotension. Diagnosing and managing coronary artery disease (CAD) by creating personalized 3D models of patients' coronary arteries from standard CT scans.
Core Technology Machine learning-based algorithm for prediction; continuous hemodynamic monitoring. Artificial intelligence (AI) for 3D modeling; Fractional Flow Reserve derived from CT (FFRct) analysis; Computational Fluid Dynamics (CFD).
Key Output/Insight HPI Parameter (0-100 likelihood score), Smart Alerts for trending hypotension, Smart Trend screen, Relationship View screen (preload, afterload, contractility insights). AI-powered 3D modeling of coronary arteries, Fractional Flow Reserve derived from CT (FFRct) analysis, Plaque Analysis (quantification and characterization), Roadmapu2122 Analysis.
Invasiveness Non-invasive (Acumen IQ cuff) and minimally-invasive (Acumen IQ sensor) options. Non-invasive diagnostic assessment.

Videos

Demos, reviews, and walkthroughs featuring Acumen Hypotension Prediction Index – EV1000 Clinical Platform and HeartFlow Analysis.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Acumen HPI integrates into real-time intraoperative and critical care workflows, providing anesthesiologists and critical care physicians with predictive insights into hemodynamic instability up to 15 minutes in advance. This allows for proactive management of hypotension by identifying potential causes through parameters like preload, afterload, and contractility. HeartFlow Analysis fits into the diagnostic pathway for coronary artery disease, enabling cardiologists and radiologists to non-invasively assess CAD severity using personalized 3D models derived from standard CT scans. This helps in guiding revascularization decisions and patient management without invasive procedures.
Acumen HPI utilizes a machine learning-based algorithm to predict hypotensive events with a 0-100 likelihood score and provides Smart Alerts for trending hypotension. Studies have shown it can predict hypotension with a sensitivity and specificity of 89% and 90% respectively, 10 minutes before an event. HeartFlow Analysis offers high diagnostic accuracy through its AI-powered 3D modeling, Fractional Flow Reserve derived from CT (FFRct) analysis, and quantitative plaque analysis. It has demonstrated diagnostic accuracy of 87%, sensitivity of 90%, and specificity of 86% on a per-vessel basis for detecting CAD.
Acumen HPI is integrated with the Edwards Lifesciences HemoSphere Advanced Monitoring Platform via dedicated sensors, suggesting a direct data flow of continuous hemodynamic monitoring and predictive parameters. This integration would facilitate the transfer of critical patient data into the EHR for comprehensive record-keeping. HeartFlow Analysis, being cloud-based, processes standard CT scans to create personalized 3D models and analyses. Its integration would involve receiving imaging data from PACS and delivering detailed diagnostic reports back to the EHR, streamlining the diagnostic workflow.
Clinicians using Acumen HPI would need training on interpreting the HPI Parameter (0-100 likelihood score), understanding Smart Alerts, and utilizing the Relationship View screen for insights into preload, afterload, and contractility. The continuous nature requires familiarity with real-time data interpretation. For HeartFlow Analysis, the learning curve would involve understanding the interpretation of AI-powered 3D models of coronary arteries, Fractional Flow Reserve derived from CT (FFRct) analysis, and quantitative plaque analysis. Clinicians would also learn to utilize Roadmap Analysis for CCTA reading.
As a continuous monitoring platform, Acumen HPI would likely generate a detailed log of HPI scores, smart alerts, and hemodynamic trends over time. This data could serve as an audit trail for reviewing clinical decisions and supporting quality improvement initiatives related to hypotension management. HeartFlow Analysis produces comprehensive reports including AI-powered 3D models, FFRct values, and plaque analysis, which inherently serve as an audit trail for diagnostic assessments. These detailed outputs can be used for retrospective review of patient cases and to inform quality improvement programs in cardiology.
Implementing Acumen HPI across multiple sites would require standardizing the Edwards Lifesciences HemoSphere Advanced Monitoring Platform and ensuring the availability of dedicated Acumen IQ cuffs or sensors at each location. This involves consistent hardware and software deployment. For HeartFlow Analysis, a cloud-based solution, multi-site rollout would primarily focus on establishing secure and efficient data transfer mechanisms for standard CT scans from various sites to the cloud. Integration of the generated reports back into each site's respective EHR/PACS would also be a key consideration.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Acumen Hypotension Prediction Index – EV1000 Clinical Platform or HeartFlow Analysis

Backers

Who funded each tool's parent company.

HeartFlow Analysis

AI Tool Finder
AI-powered search. Results may not be comprehensive.